Clinical Trial Update: Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluated the combination of saracatinib with paclitaxel in platinum-resistant ovarian cancer, including fallopian tube and primary peritoneal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Paclitaxel (Taxol) (paclitaxel)
• Saracatinib (saracatinib)

Snippet

Sponsor: University College, London | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-05-05